McDonald's Q2 Profit Soars, Results Top Estimates - Quick Facts

Fast-food giant McDonald's Corp. (MCD) reported Wednesday that net income for the second quarter soared to $2.22 billion or $2.95 per share from $483.8 million or $0.65 per share in the prior-year quarter.

Excluding items, adjusted earnings per share was $2.37, compared to last year's $0.66.

On average, 29 analysts polled by Thomson Reuters expected the company to report earnings of $2.08 per share for the quarter. Analysts' estimates typically exclude special items.

Total revenues for the quarter surged 57 percent to $5.89 billion from $3.76 billion in the same quarter last year, and it was up 49 percent in constant currencies. Analysts expected revenues of $5.53 billion for the quarter.

Global comparable sales increased 40.5 percent and increased 6.9 percent on a 2-year basis, reflecting sequential acceleration and continued broad-based business momentum. Comparable sales increased across all segments on a 2-year basis.

Systemwide sales increased 48 percent or 42 percent in constant currencies.

Results for the quarter reflected stronger operating performance across all segments due to higher sales-driven restaurant margins as a result of fewer restaurant closures and the easing of COVID-19 restrictions compared with the prior year.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Salt Lake City, Utah-based Huish Outdoors is recalling Oceanic Adult Dry Top Snorkels sold exclusively at Costco citing risk for drowning, U.S. Consumer Product Safety Commission said. The recall involves about 76,000 units of Oceanic Adult Dry Top Snorkels. The recall was initiated after Oceanic received 13 reports of the snorkels leaking. Boeing expects Europe's commercial aviation fleet to need 8,705 new airplanes through 2040 to cater to the growing leisure travel market in the region and fleet replacements with more fuel-efficient models, according to the Boeing's 2021 Commercial Market Outlook (CMO), an annual forecast of long-term demand for commercial airplanes and services. The U.S. Food and Drug Administration authorized marketing of a software developed by Paige.AI, a provider of AI-based digital diagnostics, which could help pathologists to identify prostate cancer. The software, called Paige Prostate, is the first and only artificial intelligence or AI-based pathology product to receive FDA approval for in vitro diagnostic or IVD use in detecting cancer...
Follow RTT